A colorectal cancer blood test candidate from Exact Sciences fell short in its pivotal study, but the company is still in the hunt to provide an alternative to the liquid biopsy that was first to ...

The company best known for its Cologuard colon cancer screening test posted a loss of $86 million, or $0.45 per share, on ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Joel Mokyr, Philippe Aghion and Peter Howitt have been awarded the 2025 Nobel Prize in Economics. (Photo by Jonathan Nackstrand / AFP) / ALTERNATIVE CROP (Photo by JONATHAN NACKSTRAND/AFP via Getty ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Exact Sciences announced on Wednesday that it acquired the rights to a blood-based ...

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.

North suburban-based Abbott Laboratories announced a $21 billion deal Thursday morning to acquire Exact Sciences, the maker of Cologuard — its largest acquisition in a decade. The deal will allow ...

The subject area represents the next stage of the database’s evolution, and heralds other proposed changes to journal selection and article categorization. The first Nature Index tables in the applied ...

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 5 years by 7.55% on an annualized basis producing an average annual return of 19.59%. Currently, Gilead Sciences has a market ...